Debt to Equity Ratio: A measure of a company's financial leverage calculated by dividing its long-term debt by shareholders equity. Calculated as: Total Debt / Shareholders Equity
AgomAb Therapeutics NV (AGMB) had Debt to Equity Ratio of 0.01 for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-87.68M |
|
-- |
|
-- |
|
$67.06M |
|
$-67.06M |
|
$-3.70M |
|
$-70.77M |
|
$-70.77M |
|
$-70.77M |
|
$-70.77M |
|
$-70.77M |
|
$-70.77M |
|
$-67.06M |
|
$-66.82M |
|
0.54M |
|
0.54M |
|
$-162.04 |
|
$-162.04 |
|
| Balance Sheet Financials | |
$137.17M |
|
$0.57M |
|
$36.74M |
|
$173.90M |
|
$21.03M |
|
$1.14M |
|
$4.77M |
|
$25.80M |
|
$148.10M |
|
$115.61M |
|
$148.10M |
|
0.54M |
|
| Cash Flow Statement Financials | |
$-58.54M |
|
$-37.34M |
|
$-0.38M |
|
$193.99M |
|
$97.77M |
|
$-96.22M |
|
$6.06M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.52 |
|
-- |
|
-- |
|
0.01 |
|
|
Debt to Equity Ratio |
0.01 |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-58.54M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-47.78% |
|
-61.21% |
|
-40.69% |
|
-47.42% |
|
$273.69 |
|
$-108.19 |
|
$-108.18 |
|